Showing 11-20 of 2111 results for "".
Physician Spotlight: Robert S. Kirsner, MD, PhD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-robert-s-kirsner-md-phd-faad/20319/It's time to get wound up about wound care.What ’s the Best Approach to AK Therapies? Ask an Expert
https://practicaldermatology.com/topics/skin-cancer-photoprotection/what-s-the-best-approach-to-ak-therapies-ask-an-expert/19622/Rather than consider AK a specific disease, Vishal A. Patel, MD, FAAD says it can be viewed as a marker of disease, which culminates in SCC. In this edition of Ask an Expert with Adam Friedman, MD, about his philosophy of treatment, including long-term maintenance.Research Highlights Disparities in AD Care
https://practicaldermatology.com/programs/practical-dermatology/research-highlights-disparities-in-ad-care/36472/In this episode of DermwireTV, research on socioeconomic disparities in atopic dermatitis care; new information on guselkumab for scalp psoriasis in diverse skin tones; the impact of air quality on dermatitis; and a C-Suite Chat with Anastasia Georgievskaya, founder of Haut.AI.Emrosi Launched in the US for Rosacea
https://practicaldermatology.com/series/dermwire-tv/emrosi-launched-in-the-us-for-rosacea/33943/In this week's DermwireTV, a new treatment for rosacea is launched in the US; long-term data is presented for tapinarof 1% cream for atopic dermatitis; and in our C-Suite Chats segment, we speak with the CEO and Co-Founder of Mama Sol.From SDPA: JAKs, Black Boxes, and What It All Means
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-jaks-black-boxes-and-what-it-all-means/26286/Practitioners shouldn’t fear Janus kinase (JAK) inhibitors for their patients when appropriate, according to a wide-ranging expert chat at the 2024 SDPA Annual Summer Conference in San Diego. The conversation featured Matthew Zirwas, MD, a dermatologist with DOCS Dermatology, and Amy Spizuoco, DO, FThe Best Tax Treatment for a Dermatology Practice
https://practicaldermatology.com/topics/practice-management/the-best-tax-treatment-for-a-dermatology-practice/23144/S Corp or C Corp in the post-TCJA world?DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeLong-Term Bimzelx Data Presented
https://practicaldermatology.com/series/dermwire-tv/long-term-bimzelx-data-presented/35563/In this week's DermwireTV, new long-term data is presented for Bimzelx (bimekizumab-bkzx) for two indications; an analysis examines the correlation between proximity to tanning facilities and melanoma incidence; and in our C-Suite Chats feature, we hear from the Founder and CEO of Joya Health.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.Nemluvio Gains Two Major Indications in Europe
https://practicaldermatology.com/series/dermwire-tv/nemluvio-gains-two-major-indications-in-europe/32982/In this week's DermwireTV, Nemluvio is approved for two new indications in Europe; new patient-centric guidelines for generalized pustular psoriasis (GPP) management are unveiled; and in our C-Suite Chats feature, we are joined by the Co-Founder and CEO of Veradermics.